193 related articles for article (PubMed ID: 32208128)
1. Amino Acids Sequence-based Analysis of Arginine Deiminase from Different Prokaryotic Organisms: An In Silico Approach.
Abdollahi S; Morowvat MH; Savardashtaki A; Irajie C; Najafipour S; Zarei M; Ghasemi Y
Recent Pat Biotechnol; 2020; 14(3):235-246. PubMed ID: 32208128
[TBL] [Abstract][Full Text] [Related]
2. Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L; Savaraj N
Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
[TBL] [Abstract][Full Text] [Related]
3. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
4. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
5. Rapid evolution of arginine deiminase for improved anti-tumor activity.
Ni Y; Liu Y; Schwaneberg U; Zhu L; Li N; Li L; Sun Z
Appl Microbiol Biotechnol; 2011 Apr; 90(1):193-201. PubMed ID: 21221572
[TBL] [Abstract][Full Text] [Related]
6. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
7. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
8. In silico Analysis of Different Signal Peptides for Secretory Production of Arginine Deiminase in Escherichia coli.
Zarei M; Nezafat N; Morowvat MH; Ektefaie M; Ghasemi Y
Recent Pat Biotechnol; 2019; 13(3):217-227. PubMed ID: 30621572
[TBL] [Abstract][Full Text] [Related]
9. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
10. Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.
Cheng F; Yang J; Schwaneberg U; Zhu L
Biotechnol Bioeng; 2019 Sep; 116(9):2156-2166. PubMed ID: 31062871
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
[TBL] [Abstract][Full Text] [Related]
12. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
13. Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Shen LJ; Shen WC
Curr Opin Mol Ther; 2006 Jun; 8(3):240-8. PubMed ID: 16774044
[TBL] [Abstract][Full Text] [Related]
14. Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Ni Y; Li Z; Sun Z; Zheng P; Liu Y; Zhu L; Schwaneberg U
Curr Microbiol; 2009 Jun; 58(6):593-8. PubMed ID: 19280262
[TBL] [Abstract][Full Text] [Related]
15. Arginine Deiminase: Current Understanding and Applications.
Zarei M; Rahbar MR; Morowvat MH; Nezafat N; Negahdaripour M; Berenjian A; Ghasemi Y
Recent Pat Biotechnol; 2019; 13(2):124-136. PubMed ID: 30569861
[TBL] [Abstract][Full Text] [Related]
16. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
Yang TS; Lu SN; Chao Y; Sheen IS; Lin CC; Wang TE; Chen SC; Wang JH; Liao LY; Thomson JA; Wang-Peng J; Chen PJ; Chen LT
Br J Cancer; 2010 Sep; 103(7):954-60. PubMed ID: 20808309
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
19. Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
El-Sayed ASA; Shindia AA; Zeid AAA; Yassin AM; Sitohy MZ; Sitohy B
Enzyme Microb Technol; 2019 Dec; 131():109432. PubMed ID: 31615671
[TBL] [Abstract][Full Text] [Related]
20. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
